Paper6233249
The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.
King A and 2 others. J Antimicrob Chemother, 1984. Cited by 93 papers, by iCite.
Cite this record
ConductScience Library. The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid. Papers, record 6233249. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6233249
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Bacterial Agents | Major topic |
| Bacteria | Major topic |
| Nalidixic Acid | Major topic |
| Quinolines | Major topic |
| Ciprofloxacin | |
| Drug Resistance, Microbial | |
| Humans | |
| Norfloxacin |
Source PubMed
Cited by30
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 93 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40433982 | RecN and RecA orchestrate an ordered DNA supercompaction response following ciprofloxacin-induced DNA damage in Escherichia coli. | Nucleic Acids Res | 2025 | https://conductscience.org/library/papers/40433982 | PubMed |
| 40143055 | Ciprofloxacin-Loaded Spray-Dried Lactose Particles: Formulation Optimization and Antibacterial Efficacy. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40143055 | PubMed |
| 3960690 | Quinolones in vitro. | Pharm Weekbl Sci | 1986 | https://conductscience.org/library/papers/3960690 | PubMed |
| 3908074 | Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. | Drugs | 1985 | https://conductscience.org/library/papers/3908074 | PubMed |
| 3847273 | Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals. | Antimicrob Agents Chemother | 1985 | https://conductscience.org/library/papers/3847273 | PubMed |
| 3606077 | Effects of ciprofloxacin on eucaryotic pyrimidine nucleotide biosynthesis and cell growth. | Antimicrob Agents Chemother | 1987 | https://conductscience.org/library/papers/3606077 | PubMed |
| 3606076 | 4-Quinolone drugs affect cell cycle progression and function of human lymphocytes in vitro. | Antimicrob Agents Chemother | 1987 | https://conductscience.org/library/papers/3606076 | PubMed |
| 3515312 | Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy. | Pharm Weekbl Sci | 1986 | https://conductscience.org/library/papers/3515312 | PubMed |
| 3438150 | Influence of quinolones on throat- and faecal flora of healthy volunteers. | Pharm Weekbl Sci | 1987 | https://conductscience.org/library/papers/3438150 | PubMed |
| 3286517 | Efficacy and safety of ciprofloxacin in the treatment of UTIs and RTIs in patients affected by liver diseases. | Infection | 1988 | https://conductscience.org/library/papers/3286517 | PubMed |
| 3164989 | Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureus. | Antimicrob Agents Chemother | 1988 | https://conductscience.org/library/papers/3164989 | PubMed |
| 3159749 | Ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disks. | J Clin Microbiol | 1985 | https://conductscience.org/library/papers/3159749 | PubMed |
| 3159571 | Interaction between ciprofloxacin and tobramycin or azlocillin against multiresistant strains of Acinetobacter anitratum in vitro. | Eur J Clin Microbiol | 1985 | https://conductscience.org/library/papers/3159571 | PubMed |
| 3132381 | Comparative in vitro activity of the new quinolone fleroxacin (RO 23-6240). | Eur J Clin Microbiol Infect Dis | 1988 | https://conductscience.org/library/papers/3132381 | PubMed |
| 3129373 | The relative efficacies of tobramycin and ciprofloxacin against Pseudomonas aeruginosa in vitro and in normal and granulocytopenic mice. | Infection | 1988 | https://conductscience.org/library/papers/3129373 | PubMed |
| 3124739 | Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis. | Antimicrob Agents Chemother | 1987 | https://conductscience.org/library/papers/3124739 | PubMed |
| 3053126 | Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use. | Drugs | 1988 | https://conductscience.org/library/papers/3053126 | PubMed |
| 3015015 | Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. | Antimicrob Agents Chemother | 1986 | https://conductscience.org/library/papers/3015015 | PubMed |
| 3013631 | Overview of clinical experience with ciprofloxacin. | Eur J Clin Microbiol | 1986 | https://conductscience.org/library/papers/3013631 | PubMed |
| 3000292 | The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. | Antimicrob Agents Chemother | 1985 | https://conductscience.org/library/papers/3000292 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6233249
GET https://conductscience.org/api/papers/v1/6233249/cited_by?page=2